First, we developed an overview of the precision medicine landscape and key drivers in China.
Second, we assessed each of the drivers in terms of current development, future outlook, and implications for molecular testing and companion diagnostics, with a particular focus on better efficacy, the safety profile, and clinical outcomes, as well as data generation and socioeconomic values.
Finally, we made strategic recommendations for our client to improve access and affordability of molecular testing in China and ensure seamless access and GTM synergy with the client’s new oncology asset.